{"id":62497,"date":"2026-01-15T04:06:03","date_gmt":"2026-01-15T03:06:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/"},"modified":"2026-01-15T04:06:03","modified_gmt":"2026-01-15T03:06:03","slug":"samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/","title":{"rendered":"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030<\/i><\/li>\n<li>\n<i>The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studies<\/i><\/li>\n<li>\n<i>Having secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis\u2019 novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this year<\/i><\/li>\n<li>\n<i>Samsung Bioepis plans to add one novel therapeutic candidate in clinical study every year<\/i><\/li>\n<\/ul>\n<p>\n\u00a0<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/5\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/22\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/5\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/21\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691778\/5\/Samsung_Epis_Holdings_English_signature_vertical.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691778\/22\/Samsung_Epis_Holdings_English_signature_vertical.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691778\/5\/Samsung_Epis_Holdings_English_signature_vertical.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691778\/21\/Samsung_Epis_Holdings_English_signature_vertical.jpg\"><\/a><\/p>\n<p>INCHEON, Korea&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ADC?src=hash\" target=\"_blank\">#ADC<\/a>&#8211;Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference.<\/p>\n<p>\n&#8220;2026 is a monumental year for us, as we enter into a new chapter for our company. Today, we are announcing six additional candidates in our biosimilar pipeline, including vedolizumab and dupilumab. We are making great progress to secure 20 biosimilars in our portfolio by 2030,&#8221; said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. \u201cWe also received the investigational new drug application (IND) clearance for the first novel therapeutic candidate developed by Samsung Bioepis, and plan to advance our clinical program this year. As we broaden our portfolio beyond biosimilars, we will continue our development efforts in antibody-drug conjugates (ADCs), leveraging our innovative research and development platform to expand viable treatment options for patients with unmet needs.\u201d<\/p>\n<p>\n<b>Samsung Bioepis Biosimilar Updates<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSamsung Bioepis currently has 11 biosimilars for 10 unique biological molecules approved and launched in more than 40 countries.<sup>1<\/sup> The company has pembrolizumab biosimilar undergoing Phase 1 and 3 clinical studies, and plans to secure 20 biosimilars in its portfolio by 2030.<\/li>\n<li>\nThe new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab.<\/li>\n<\/ul>\n<p>\n<b>Novel Therapeutics Updates<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn December 2025, the FDA has cleared the IND Application for SBE303. SBE303 is Samsung Bioepis\u2019 first novel ADC engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.<sup>2<\/sup> The Phase 1 first-in-human clinical trial, aiming to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of SBE303 in participants with advanced refractory solid tumors, is set to begin this year.<\/li>\n<li>\nSamsung Bioepis plans to have one novel therapeutic candidate enter into clinical study every year.<\/li>\n<li>\nEpis NexLab, the new subsidiary under Samsung Epis Holdings, has launched a project to develop a peptide-based drug delivery platform.<\/li>\n<\/ul>\n<p>\n<b>Samsung Bioepis Biosimilars Portfolio<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Code Name (Brand Name<sup>3<\/sup>)<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Non-proprietary Name<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Reference Product<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Status<sup>4<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB5<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(IMRALDI\u2122, HADLIMA\u2122, ADALLOCE\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAdalimumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nHumira<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB4<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(BENEPALI\u2122, BRENZYS\u2122, ETOLOCE\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEtanercept<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEnbrel<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB2<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(FLIXABI\u2122, RENFLEXIS\u2122, REMALOCE\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nInfliximab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nRemicade<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB3<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(ONTRUZANT\u2122, SAMFENET\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nTrastuzumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nHerceptin<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB8<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(AYBINTIO\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nBevacizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAvastin<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB11<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(BYOOVIZ\u2122, AMELIVU\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nRanibizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLucentis<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB12<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(EPYSQLI\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEculizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSoliris<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB15<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(OPUVIZ\u2122, AFILIVU\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAflibercept<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEylea<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB16<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(OBODENCE\u2122, OSPOMYV\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nDenosumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nProlia<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB16<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(XBRYK\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nDenosumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nXgeva<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB17<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(PYZCHIVA\u2122, EPYZTEK\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nUstekinumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nStelara<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB27<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nPembrolizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nKeytruda<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nPhase 1 and 3<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Samsung Bioepis Biosimilar Candidates in Early Stage Development<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Non-proprietary Name<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Reference Product<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDupilumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDupixent<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGuselkumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTremfya<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIxekizumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTaltz<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVedolizumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEntyvio<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOcrelizumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOcrevus<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFam-trastuzumab deruxtecan-nxki<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEnhertu<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About Samsung Epis Holdings Co., Ltd.<\/b><\/p>\n<p>\nAs an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&amp;D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungepisholdings.com&amp;esheet=54396262&amp;newsitemid=20260114206458&amp;lan=en-US&amp;anchor=www.samsungepisholdings.com&amp;index=1&amp;md5=7af297cda172a0f061e7d1ece808f3c1\" rel=\"nofollow\" shape=\"rect\">www.samsungepisholdings.com<\/a>.<\/p>\n<p>\n<b>About Samsung Bioepis Co., Ltd.<\/b><\/p>\n<p>\nEstablished in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world&#8217;s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=54396262&amp;newsitemid=20260114206458&amp;lan=en-US&amp;anchor=www.samsungbioepis.com&amp;index=2&amp;md5=ed3a3dc5a9f80ec044db46c06e03d377\" rel=\"nofollow\" shape=\"rect\">www.samsungbioepis.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis%2F&amp;esheet=54396262&amp;newsitemid=20260114206458&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=59db2e1e2446442934c4944961fea329\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSamsungBioepis&amp;esheet=54396262&amp;newsitemid=20260114206458&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=2cb151a52ee954a6a9715b2d00a4ac7d\" rel=\"nofollow\" shape=\"rect\">X<\/a>.<\/p>\n<p>\n<b>About Epis NexLab Co., Ltd.<\/b><\/p>\n<p>\nEstablished in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungepisholdings.com&amp;esheet=54396262&amp;newsitemid=20260114206458&amp;lan=en-US&amp;anchor=www.samsungepisholdings.com&amp;index=5&amp;md5=d73f1a6e0cfc6be95784125d6e338652\" rel=\"nofollow\" shape=\"rect\">www.samsungepisholdings.com<\/a>.<\/p>\n<p>\n<sup>1<\/sup> \u201cmore than 40 countries\u201d signifies countries where Samsung Bioepis has commercial presence, with one or more products.<br \/>\n<br \/><sup>2<\/sup> Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389\/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101.<br \/>\n<br \/><sup>3<\/sup> Different brand names for different regions and countries.<br \/>\n<br \/><sup>4<\/sup> \u201cLaunch\u201d signifies launch in one or more markets and does not necessarily indicate launch in all markets worldwide<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact<\/b><br \/>Anna Nayun Kim, <a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#110;&#x61;&#121;&#x75;n&#x38;6&#46;&#x6b;&#105;&#x6d;&#64;&#x73;a&#109;&#x73;&#117;&#x6e;g&#x2e;c&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">n&#97;&#x79;&#x75;&#x6e;8&#54;&#46;&#x6b;&#x69;m&#64;&#115;&#x61;&#x6d;su&#110;&#x67;&#x2e;&#x63;o&#109;<\/a><br \/>Yoon Kim, <a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;&#x3a;&#x79;o&#x6f;&#110;&#x31;&#46;&#x6b;&#105;m&#x40;&#115;&#x61;&#109;&#x73;&#117;n&#x67;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x79;&#111;&#x6f;&#x6e;&#49;&#x2e;&#x6b;&#105;&#x6d;&#x40;&#115;&#x61;&#x6d;s&#x75;&#x6e;g&#x2e;&#99;o&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studies Having secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62497","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studies Having secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T03:06:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/22\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference\",\"datePublished\":\"2026-01-15T03:06:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":848,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114206458\\\/en\\\/2691779\\\/22\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114206458\\\/en\\\/2691779\\\/22\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\",\"datePublished\":\"2026-01-15T03:06:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114206458\\\/en\\\/2691779\\\/22\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114206458\\\/en\\\/2691779\\\/22\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference - Pharma Trend","og_description":"Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studies Having secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-15T03:06:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/22\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference","datePublished":"2026-01-15T03:06:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/"},"wordCount":848,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/22\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/","name":"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/22\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","datePublished":"2026-01-15T03:06:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/22\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260114206458\/en\/2691779\/22\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/samsung-epis-holdings-delivers-business-updates-at-the-44th-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62497"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62497\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}